3-Bromopyruvic acid.|1113-59-3|(3-溴丙酮酸; Bromopyruvic acid; Hexokinase II Inhibitor II, 3-BP)-陌孚医药/Medlife

您当前的位置：

3-Bromopyruvic acid. (Synonyms: 3-溴丙酮酸; Bromopyruvic acid; Hexokinase II Inhibitor II, 3-BP)

目录号: PC16929 纯度: ≥98%

CAS No. :1113-59-3

商品编号	规格	价格	会员价
PC16929-1g	1g	¥490.00	请登录
PC16929-5g	5g	¥686.00	请登录
PC16929-10g	10g	¥931.00	请登录
PC16929-25g	25g	¥1862.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	3-Bromopyruvic acid.
中文别名	3-溴丙酮酸;3-溴庚酸;溴丙酮酸;3-溴代丙酮酸;3-Bromopyruvic Acid 3-溴丙酮酸;3-溴***酸;3-溴-2-氧代丙酸
英文名称	3-Bromopyruvic acid
英文别名	3-Bromopyruvic acid;3-BROMO-2-OXOPROPANOIC ACID;3-BROMO-2-OXOPROPIONIC ACID;BROMOPYRUVIC ACID;3-bromo-2-oxo-propanoicaci;3-bromopyruvate;beta-bromopyruvicacid;bromopyruvate;bromo-pyruvicaci;3-BROMOPYRUVIC ACID CRYSTALLINE;Bromopyruvicacidhydrate;3-BROMO-2-OXOPROPANOICACID(3-BROMOPYRUVICACID);2-Oxo-3-bromopropanoic acid;2-Oxo-3-bromopropionic acid;3-BROMO-2-OXO-PROPIONIC ACID;3-BromopYHuvic acid;3-BROMOPYRUVIC ACID HYDRATE;3-BROMOPYRUVICACID(3-BROMOPYRUVATE);Hexokinase II Inhibitor II, 3-BP;PROPANOIC ACID,3-BROMO-2-OXO-
Cas No.	1113-59-3
分子式	C₃H₃BrO₃
分子量	166.96
包装储存	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

生物活性

3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities.

性状

Solid

体外研究(In Vitro)

3-Bromopyruvate enhances TRAIL-induced apoptosis in breast cancer cells.
3-Bromopyruvate (Bromopyruvic acid), a hexokinase II inhibitor, can induce apoptosis in hepatocellular carcinoma cells by inducing endoplasmic reticulum (ER) stress.
3-Bromopyruvate inhibits ATP generation and upregulates the expression of DR5. 3-Bromopyruvate upregulates CHOP, GRP78 and the phosphorylation of AMPK and augments TRAIL-induced Bax and caspase-3 levels.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	MCF-7 and MDA-MB-231 cells
Concentration:	40, 80, 160 or 320 μM
Incubation Time:	24 hours
Result:	3-Bromopyruvate (80 and 160 μmol/l) and TRAIL (400 ng/ml) significantly inhibited cell viability.

体内研究(In Vivo)

3-Bromopyruvate (8 mg/kg; i.p.; every 4 days for 28 days) shows a synergistic antitumor effect in MCF-7 cell xenografts in nude mice.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice (BALB/c; 4-5-weeks old and 18-20 g)
Dosage:	8 mg/kg
Administration:	I.p.; every 4 days for 28 days
Result:	Showed antitumor efficacy in tumor xenografts.

运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

[1]. Gan L, et al. Synergistic Effect of 3-Bromopyruvate in Combination with Rapamycin Impacted Neuroblastoma Metabolism by Inhibiting Autophagy. Onco Targets Ther. 2020;13:11125-11137. Published 2020 Oct 29. [Information]

[2]. Chen Y, et al. 3 Bromopyruvate sensitizes human breast cancer cells to TRAIL induced apoptosis via the phosphorylated AMPK mediated upregulation of DR5. Oncol Rep. 2018;40(5):2435-2444. [Information]

[3]. Zhang Q, et al. Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer. 2014;5(3-4):100-112. [Information]

溶解度数据

体外研究:

H₂O : 250 mg/mL (1497.36 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.9895 mL	29.9473 mL	59.8946 mL
5 mM	1.1979 mL	5.9895 mL	11.9789 mL
10 mM	0.5989 mL	2.9947 mL	5.9895 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 100 mg/mL (598.95 mM); Clear solution; Need ultrasonic

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation